Clinical trials: Lymphatic Malformations
Vascular Malformations, Arteriovenous Malformations
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Background and Objectives Vascular anomalies are a heterogeneous group of disorders classified into vascular tumors and vascular malformations according to the ISSVA classification.
- Conditions
- Vascular Malformations, Arteriovenous Malformations, Venous Malformation, Lymphangioma
- Trial name
- NCT07477548
- Testing
- Everolimus
- Volunteers
- 67 people
- Sponsor
- Yonsei University
Vascular Malformations, Venous Malformation
Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and Neck
This study evaluated lesion volume reduction after intralesional bleomycin sclerotherapy in patients with low-flow vascular malformations of the head and neck, and identified predictors of treatment response.
- Conditions
- Vascular Malformations, Venous Malformation, Lymphatic Malformation
- Trial name
- NCT07728825
- Testing
- Bleomycin (Bleocel 15)
- Where
- 3 sites in Iraq
- Volunteers
- 20 people
- Sponsor
- University Of Anbar
Kaposiform Hemangioendotheliomas, Tufted Angioma
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved…
- Conditions
- Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation
- Trial name
- NCT00975819
- Testing
- sirolimus
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Denise Martin Adams
Lymphatic Malformation
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of cystic lymphatic malformation.
- Trial name
- NCT06673290
- Testing
- Sirolimus (RAPAMUNE)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- West China Hospital
Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients.
- Conditions
- Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, Asthma, COPD
- Trial name
- ExercisePAVM2 (NCT02458703)
- Testing
- Cardiopulmonary exercise test
- Volunteers
- 60 people
- Sponsor
- Imperial College London
22Q11 Deletion Syndrome, tACS
Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome
The purpose of this project is to explore the effects of transcranial alternating current stimulation (tACS) in children, adolescents and young adults with a 22q11.2 microdeletion.
- Trial name
- NCT05664412
- Testing
- at-home tACS using Starstim-Home tES
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Stephan Eliez
Microcystic Lymphatic Malformation
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
- Trial name
- NCT05050149
- Testing
- PTX-022
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Palvella Therapeutics, Inc.
Telangiectasia, Hereditary Hemorrhagic
Studies of Hereditary Hemorrhagic Telangiectasia
OBJECTIVES: I. Examine screening modalities for pulmonary vascular arteriovenous malformation (PAVM) in individuals with endoglin mutations. II.
- Trial name
- NCT00004648
- Volunteers
- 65 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia, Dental Diseases
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
HHT is a relative rare autosomal dominant inherited disorder of the fibrovascular tissue. Diagnosis of HHT is often delayed for decades (Pierucci 2012).
- Trial name
- NCT03549949
- Where
- Germany
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Orbital Lymphatic Malformation
Systematic Approach for Children With Orbital Malformation With Sirolimus Use
The goal of this interventional study is to Set a systematic management approach for orbital lymphatic malformation and to study the safety and efficacy of sirolimus in children and adolescents with orbital lymphatic…
- Trial name
- sirolimus (NCT07378657)
- Testing
- Injection Sclerotherapy, Sirolimus (Rapamune®), both injection sclerotherapy and sirolimus
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Microcephaly
Microcephaly Genetic Deficiency in Neural Progenitors
The purpose of this study is to: I. Compare neuroradiological phenotype and cognitive functioning of MCPH patients caused by ASPM mutations already characterized and published (Passemard et al.
- Trial name
- MICROFANC (NCT01565005)
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
22q11.2 Deletion Syndrome
Arithmetic Abilities in Children With 22q11.2DS
The study ARITH22 will investigate the role of visuo-spatial attention on arithmetic abilities of children with 22q11.2 deletion syndrome.
- Trial name
- ARITH22 (NCT04373226)
- Testing
- Magnitude comparison tasks and neuropsychological testing
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Telangiectasia, Hereditary Hemorrhagic
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs).
- Trial name
- NCT00230672
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
DiGeorge Syndrome, Congenital Heart Defects
Infection in DiGeorge Following CHD Surgery
We propose a retrospective review of patients with DiGeorge syndrome having undergone cardiac surgery to evaluate the incidence of blood stream and/or surgical site infection.
- Trial name
- NCT00278005
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Children's Healthcare of Atlanta
Lymphatic Malformation
A Prospective Study on the Treatment of cLM Based on ICG Imaging
The goal of this prospective randomized controlled study is to explore the role of indocyanine green-fluorescence imaging in management of cystic lymphatic malformation..
- Trial name
- NCT06275022
- Testing
- Inflow occlusion with perforation of septation and sclerotherapy, Perforation of septation and sclerotherapy, Indocyanine green-guided partial resection and sclerotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Nanjing Children's Hospital
DiGeorge Syndrome, Complete Typical DiGeorge Anomaly
Thymus Transplantation in DiGeorge Syndrome #668
The study purpose is to determine whether cultured thymus tissue implantation (CTTI) is effective in treating typical complete DiGeorge syndrome.
- Trial name
- NCT00576407
- Testing
- Cultured Thymus Tissue for Implantation (CTTI)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH